Eli Lilly's Foundayo Cuts Death Risk 57%, Readies FDA Filing and $6.3B Deal
Foundayo met cardiovascular safety goals in its Phase 3 ACHIEVE-4 trial with non-inferior major adverse event risk and a 57% lower all-cause death rate, triggering an FDA submission by Q2 2026 despite previous safety concerns. Lilly struck a $6.3 billion upfront deal with $1.5 billion in milestones and set its Q1 call for April 30.
1. Foundayo Achieves Cardiovascular Safety
In the Phase 3 ACHIEVE-4 trial, Foundayo delivered non-inferior risk of major adverse cardiovascular events compared to insulin glargine and achieved a 57% reduction in all-cause mortality. These safety and efficacy metrics underpin Lilly’s plan to submit for FDA approval in Q2 2026, addressing earlier concerns over liver and gastric effects.
2. Major Acquisition Deal
Lilly agreed to an upfront payment of $6.3 billion with potential milestone payouts up to $1.5 billion under a strategic partnership aimed at expanding its pipeline. The transaction strengthens Lilly’s long-term growth prospects in emerging therapeutic areas and underscores its commitment to high-value assets.
3. Q1 2026 Earnings Call Scheduled
Eli Lilly will report first-quarter 2026 results on April 30 and host a conference call at 10 a.m. Eastern time to review performance and strategic initiatives. A live webcast and replay will be accessible via Lilly’s investor website, allowing stakeholders to engage with management insights.